Research Grants

In order to facilitate therapy development and ultimately find a cure, the PKD Foundation awarded research grants to 15 PKD researchers. The PKD Foundation will spend nearly $2.4 million over the next two years on these grants through the Research Grant Program.

 

For summaries of the projects grant recipients are conducting, please click here or read below.

Dr. Vincent H. Gattone Research Award for the Top-Rated Grant Proposal
Funded by The Carlo and Micol Schejola Foundation

Advancing HSP90 Inhibitors Towards Clinical Trials for ADPKD

Erica Golemis, Ph.D.
The Research Institute of Fox Chase Cancer Center
(Therapy Development)

View Summary


International Awardees

The Eileen Creamer O'Neill Award

Targeting Glucose Metabolism in PKD: A Preclinical Proof-of-Concept Study*

Alessandra Boletta, Ph.D.
Fondazione Centro San Raffaele
(Therapy Development)

View Summary

Health Care Utilization and Costs of ADPKD

York Pei, M.D.
University of Toronto General Hospital

View Summary

Effects of Genetic and Pharmacological Ablation (Deletion) of KCNN4 on Disease Progression in Two Orthologous Mouse Models of PKD

Marie Trudel, Ph.D.
Institut de Recherches Cliniques de Montreal
(Therapy Development)

View Summary


United States Awardees

Role of CFTR and NKCC1 in PKD

James Calvet, Ph.D.
University of Kansas Medical Center
(Discovery Research)

View Summary

Preclinical Assessment of MCP-1/CCR2 Inhibition as Treatment for ADPKD

Timothy Fields, M.D., Ph.D., and Katherine Swenson-Fields, Ph.D.
University of Kansas Medical Center
(Therapy Development)

View Summary

Investigation of the Biological Basis and Therapeutic Effect of Anti-tumor Drug 11beta-dichloro on PKD*

Anna Rachel Gallagher, Ph.D.
Yale University
(Therapy Development)

View Summary

The Role of Beta-catenin as Signal Integrator in PKD

Jordan Kreidberg, M.D., Ph.D.
Boston Children's Hospital
(Discovery Research)

View Summary

Role of Tulp3 and the Hedgehog Pathway in PKD

Karel Liem, Jr., M.D., Ph.D.
Yale University
(Discovery Research)

View Summary

The Effects of Genetic Reactivation of Functional Polycystins on Progression of PKD*

Ming Ma, Ph.D.
Yale University
(Discovery Research)

View Summary

Role of miR-17~92 in the Pathogenesis of PKD

Vishal Patel, M.D.
University of Texas Southwestern Medical Center
(Discovery Research)

View Summary

Unifying Cystogenic Mechanism of ADPKD and ARPKD*

Feng Qian, Ph.D.
University of Maryland Medical Center: Division of Nephrology
(Discovery Research)

View Summary

HDAC Inhibitor Mediated Kidney Cyst Reduction

Zhaoxia Sun, Ph.D.
Yale University
(Discovery Research)

View Summary

The Rosemary M. Peppet Award

Phosphodiesterase/cAMP Signaling in Renal Cystogenesis (Cyst Formation) in Zebrafish

Caroline Sussman, Ph.D.
Mayo Clinic
(Discovery Research)

View Summary

In Vivo Analysis of Cilia Mechanosensation in the Kidney

Bradley Yoder, Ph.D.
University of Alabama at Birmingham
(Discovery Research)

View Summary

Key facts and definitions:

  • In PKD, fluid-filled cysts develop and enlarge in both kidneys, eventually leading to kidney failure.
  • ADPKD can be inherited in a dominant way from mutations in the PKD1 or PKD2 genes.
  • ARPKD can be inherited in a recessive way from mutations in the PKDH1 gene.
  • A channel is a way for charged particles to move across the membranes of cells.
  • A cell pathway is a biochemical pathway through which cells signal each other.
  • Rodent models include rats and mice with PKD.
  • A drug target is a naturally existing compound in the cell the drug is meant to act on.
  • It is important to note that discovery research that focuses on understanding the way in which cysts develop or enlarge in PKD must be conducted in order to identify cell compounds and pathways before therapy development can be done.

Your Organization

2000 Daniel Island Drive, Charleston SC 29492
Phone: 800.443.9441 | Fax: 843.216.6100
info@yourdomain.org

©2014, PKD Foundation ·The PKD Foundation is a 501 (c)(3), 509 (a)(1) public charity.

©2014, PKD Foundation ·The PKD Foundation is a 501 (c)(3), 509 (a)(1) public charity.

The PKD Foundation is a 501 (c)(3), 509 (a)(1) public charity.
National Headquarters: 8330 Ward Parkway, Suite 510, Kansas City, MO 64114. Phone: 1.800.PKD.CURE
©2014 PKD Foundation. Privacy Policy | Terms & Conditions

Founded in 1982, our vision is that one day,
no one will suffer the full effects of polycystic kidney disease.


International: Canada Canada  France France  Germany Germany  Italy Italy  Japan Japan  United Kingdom United Kingdom